PMID- 30188189
OWN - NLM
STAT- MEDLINE
DCOM- 20190808
LR  - 20190808
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 14
IP  - 30
DP  - 2018 Dec
TI  - Management of challenging immune-related gastrointestinal adverse events 
      associated with immune checkpoint inhibitors.
PG  - 3187-3198
LID - 10.2217/fon-2018-0509 [doi]
AB  - Immune-related gastrointestinal toxicities (irGI) are well-known adverse events 
      (AEs) with immune checkpoint inhibitors. The aim of this review was to present 
      clinical data from 82 cases to provide information to clinicians who face 
      real-world challenges among their patients with irGI AEs. The findings of this 
      review support the use of the current management guidelines. By analyzing the 
      treatment courses and outcomes of all cases identified, our review recommends 
      that recurrent cases be treated carefully regardless of the grade of diarrhea at 
      the onset of events. Earlier gastroenterology consultation and computed 
      tomography/endoscopy diagnosis are essential, especially when an irGI AE recurs 
      or worsens during steroid tapering. We would also suggest earlier decision to add 
      immunosuppressant agents, particularly for recurrent cases.
FAU - Hamamoto, Yasuo
AU  - Hamamoto Y
AD  - Keio Cancer Center, Keio University School of Medicine, Shinjuku-ku, Tokyo, 
      Japan.
FAU - Shin, Natalya
AU  - Shin N
AD  - Research and Development Department, Division of Pharmacovigilance, Bristol-Myers 
      Squibb K.K., Shinjuku-ku, Tokyo, Japan.
FAU - Hoshino, Tomohiro
AU  - Hoshino T
AD  - Safety Strategy 2, Safety management, Division of Pharmacovigilance, Ono 
      Pharmaceutical Co., Ltd, Chuo-ku, Osaka, Japan.
FAU - Kanai, Takanori
AU  - Kanai T
AD  - Department of Internal Medicine, Division of Gastroenterology & Hepatology, Keio 
      University School of Medicine, Shinjuku-ku, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20180906
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Ipilimumab)
RN  - 31YO63LBSN (Nivolumab)
MH  - Animals
MH  - Antineoplastic Agents, Immunological/*adverse effects/therapeutic use
MH  - Biomarkers, Tumor
MH  - Diagnostic Imaging/methods
MH  - Disease Management
MH  - Gastrointestinal Diseases/*diagnosis/*etiology/*therapy
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Ipilimumab/adverse effects/therapeutic use
MH  - Molecular Targeted Therapy/adverse effects
MH  - Neoplasms/*complications/drug therapy/immunology
MH  - Nivolumab/adverse effects/therapeutic use
OTO - NOTNLM
OT  - colitis
OT  - diarrhea
OT  - immune checkpoint inhibitors
OT  - immune-related adverse events
OT  - ipilimumab
OT  - nivolumab
EDAT- 2018/09/07 06:00
MHDA- 2019/08/09 06:00
CRDT- 2018/09/07 06:00
PHST- 2018/09/07 06:00 [pubmed]
PHST- 2019/08/09 06:00 [medline]
PHST- 2018/09/07 06:00 [entrez]
AID - 10.2217/fon-2018-0509 [doi]
PST - ppublish
SO  - Future Oncol. 2018 Dec;14(30):3187-3198. doi: 10.2217/fon-2018-0509. Epub 2018 
      Sep 6.